During the last session, Bionano Genomics, Inc. (NASDAQ:BNGO)’s traded shares were 14,099,059, with the beta value of the company hitting 0. At the end of the trading day, the stock’s price was $7.4, reflecting an intraday loss of -5.73% or -$0.45. The 52-week high for the BNGO share is $15.69, that puts it down -112.03% from that peak though still a striking +96.22% gain since the share price plummeted to a 52-week low of $0.28. The company’s market capitalization is $2.06 Billion, and the average intraday trading volume over the past 10 days was 16.86 Million shares, and the average trade volume was 55.02 Million shares over the past three months.
Bionano Genomics, Inc. (BNGO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.7. BNGO has a Sell rating from none of the analyst(s) out of 3 analysts who have looked at this stock. Neither of the analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 3 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.04.
Bionano Genomics, Inc. (NASDAQ:BNGO): Trading Information
Bionano Genomics, Inc. (BNGO) registered a -5.73% downside in the last session and has traded in the red over the past 5 sessions. The stock spiked 12.22% in intraday trading to $8.43- this Thursday, Apr 01, hitting a weekly high. The stock’s 5-day price performance is -4.15%, and it has moved by 3.5% in 30 days. Based on these gigs, the overall price performance for the year is 140.26%. The short interest in Bionano Genomics, Inc. (NASDAQ:BNGO) is 23.78 Million shares and it means that shorts have 0.43 day(s) to cover.
The consensus price target of analysts on Wall Street is $14.33, which implies an increase of 93.65% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $14 and $15 respectively. As a result, BNGO is trading at a discount of 102.7% off the target high and 89.19% off the low.
Bionano Genomics, Inc. (BNGO) projections and forecasts
Statistics show that Bionano Genomics, Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Bionano Genomics, Inc. (BNGO) shares have gone up +1099.74% during the last six months, with a year-to-date growth rate less than the industry average at -53.85% against 8.4%. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 86.7% this quarter and then jump 44.4% in the quarter after that. In the rating firms’ projections, revenue will increase 92.2% compared to the previous financial year.
Revenue for the current quarter is expected to be $2.97 Million as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to $3.59 Million by the end of June 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $1.14 Million and $1.18 Million respectively. In this case, analysts expect current quarter sales to grow by 160.5% and then jump by 203.7% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings fell an estimated 0%. While earnings are projected to return 80.2% in 2021, the next five years will return 0% per annum.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Bionano Genomics, Inc. (NASDAQ:BNGO)’s Biggest Investors
Bionano Genomics, Inc. insiders own 0.03% of total outstanding shares while institutional holders control 4.59%, with the float percentage being 4.59%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 52 institutions own stock in it. As of Dec 30, 2020, the company held over 7.13 Million shares (or 2.56% of all shares), a total value of $21.97 Million in shares.
The next largest institutional holding, with 2.1 Million shares, is of Pura Vida Investments, LLC’s that is approximately 0.75% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $6.47 Million.
Also, the Mutual Funds coming in first place with the largest holdings of Bionano Genomics, Inc. (BNGO) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2020 indicates that Vanguard Total Stock Market Index Fund owns about 4,945,464 shares. This amounts to just over 1.77 percent of the company’s overall shares, with a $15.23 Million market value. The same data shows that the other fund manager holds slightly less at 1.45 Million, or about 0.52% of the stock, which is worth about $4.47 Million.